Evaluating photodynamic therapy response in head and neck cancer with EGFR ‐targeted paired‐agent imaging

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Reeham Choudhury, Sanjana Pannem, Yichen Feng, Sassan Hodge, Kimberley S. Samkoe
Format: Artículo Open Access
Published: Wiley 2026
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867016836014407680
author Reeham Choudhury
Sanjana Pannem
Yichen Feng
Sassan Hodge
Kimberley S. Samkoe
author_facet Reeham Choudhury
Sanjana Pannem
Yichen Feng
Sassan Hodge
Kimberley S. Samkoe
Reeham Choudhury
Sanjana Pannem
Yichen Feng
Sassan Hodge
Kimberley S. Samkoe
collection Wiley Open Access
contents Evaluating photodynamic therapy response in head and neck cancer with EGFR ‐targeted paired‐agent imaging Reeham Choudhury Sanjana Pannem Yichen Feng Sassan Hodge Kimberley S. Samkoe Photochemistry and Photobiology Abstract Head and neck cancer (HNC) affects thousands globally, with high morbidity rates due to standard treatments like surgery and radiation. Photodynamic therapy (PDT) has shown great promise as a less destructive alternative, selectively targeting tumors while preserving healthy tissue. However, assessing treatment response in the days after PDT is challenging due to significant inflammation and the subsequent vascular shutdown of the tumor. We hypothesize that fluorescence paired‐agent imaging (PAI) can provide early molecular insights within 24 h of PDT to evaluate treatment efficacy. PAI utilizes two fluorescent agents to correct for perfusion‐related changes, allowing for accurate quantification of key signaling proteins. Specifically, we tracked epidermal growth factor receptor (EGFR) response to benzoporphyrin derivative monoacid (BPD)‐PDT at 690 nm, with light fluences ranging from 0 to 100 J/cm 2 . Twenty‐four hours post‐PDT, EGFR concentrations were measured using PAI with ABY‐029 and IRDye 680LT as targeted and untargeted agents, respectively. These findings were compared to histopathology (H&E and EGFR IHC). Our histological results demonstrated that EGFR expression increased with low PDT doses (10 and 25 J/cm 2 ) and decreased below baseline expression with higher doses (50 and 100 J/cm 2 ). Fluorescence intensity of both ABY‐029 and IRDye 680LT was highly variable with treatment dose and was not correlative to tumor response. In contrast, the PAI‐binding potential (BP) corresponded to the varying EGFR expression measured by pathology. In   vivo and ex   vivo PAI BP was moderately to highly correlative to percent area IHC EGFR expression ( r  = 0.65 and 0.54, p  < 0.05, respectively) and the in   vivo 100 J/cm 2 treatment group demonstrated significantly lower BP than the controls. PAI emerges as a promising tool for tracking early molecular changes in HNC, with potential clinical applications. 10.1111/php.70076 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1111/php.70076
format Artículo Open Access
id wiley_oa_10_1111_php_70076
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle Evaluating photodynamic therapy response in head and neck cancer with EGFR ‐targeted paired‐agent imaging
Reeham Choudhury
Sanjana Pannem
Yichen Feng
Sassan Hodge
Kimberley S. Samkoe
Photochemistry and Photobiology
Evaluating photodynamic therapy response in head and neck cancer with EGFR ‐targeted paired‐agent imaging Reeham Choudhury Sanjana Pannem Yichen Feng Sassan Hodge Kimberley S. Samkoe Photochemistry and Photobiology Abstract Head and neck cancer (HNC) affects thousands globally, with high morbidity rates due to standard treatments like surgery and radiation. Photodynamic therapy (PDT) has shown great promise as a less destructive alternative, selectively targeting tumors while preserving healthy tissue. However, assessing treatment response in the days after PDT is challenging due to significant inflammation and the subsequent vascular shutdown of the tumor. We hypothesize that fluorescence paired‐agent imaging (PAI) can provide early molecular insights within 24 h of PDT to evaluate treatment efficacy. PAI utilizes two fluorescent agents to correct for perfusion‐related changes, allowing for accurate quantification of key signaling proteins. Specifically, we tracked epidermal growth factor receptor (EGFR) response to benzoporphyrin derivative monoacid (BPD)‐PDT at 690 nm, with light fluences ranging from 0 to 100 J/cm 2 . Twenty‐four hours post‐PDT, EGFR concentrations were measured using PAI with ABY‐029 and IRDye 680LT as targeted and untargeted agents, respectively. These findings were compared to histopathology (H&E and EGFR IHC). Our histological results demonstrated that EGFR expression increased with low PDT doses (10 and 25 J/cm 2 ) and decreased below baseline expression with higher doses (50 and 100 J/cm 2 ). Fluorescence intensity of both ABY‐029 and IRDye 680LT was highly variable with treatment dose and was not correlative to tumor response. In contrast, the PAI‐binding potential (BP) corresponded to the varying EGFR expression measured by pathology. In   vivo and ex   vivo PAI BP was moderately to highly correlative to percent area IHC EGFR expression ( r  = 0.65 and 0.54, p  < 0.05, respectively) and the in   vivo 100 J/cm 2 treatment group demonstrated significantly lower BP than the controls. PAI emerges as a promising tool for tracking early molecular changes in HNC, with potential clinical applications. 10.1111/php.70076 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Evaluating photodynamic therapy response in head and neck cancer with EGFR ‐targeted paired‐agent imaging
topic Photochemistry and Photobiology
url https://onlinelibrary.wiley.com/doi/10.1111/php.70076